Research and Development
This group unites PF patients, caregivers, researchers and medical professionals in a platform to... View more
LOXL2 Inhibitor Shows Promise in Phase 1 Pulmonary Fibrosis Trial
-
LOXL2 Inhibitor Shows Promise in Phase 1 Pulmonary Fibrosis Trial
Pharmaxis’ first small molecule inhibitor of LOXL2 was found safe and well tolerated in a Phase 1 trial in healthy volunteers. Click here to learn more.
What do you think about this news?
Sorry, there were no replies found.
Log in to reply.